Karina J. Yoon

1.5k total citations
48 papers, 1.1k citations indexed

About

Karina J. Yoon is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Karina J. Yoon has authored 48 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 22 papers in Oncology and 19 papers in Neurology. Recurrent topics in Karina J. Yoon's work include Neuroblastoma Research and Treatments (19 papers), Protein Degradation and Inhibitors (10 papers) and Cancer Cells and Metastasis (7 papers). Karina J. Yoon is often cited by papers focused on Neuroblastoma Research and Treatments (19 papers), Protein Degradation and Inhibitors (10 papers) and Cancer Cells and Metastasis (7 papers). Karina J. Yoon collaborates with scholars based in United States, Canada and South Korea. Karina J. Yoon's co-authors include Patrick L. Garcia, Aubrey L. Miller, Mary K. Danks, Robert C.A.M. van Waardenburg, Eddy S. Yang, Joanna S. Remack, James E. Bradner, Philip M. Potter, Elizabeth A. Beierle and Elizabeth Garcia and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Karina J. Yoon

45 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karina J. Yoon United States 18 777 409 168 152 128 48 1.1k
Barbara Tanno Italy 19 737 0.9× 423 1.0× 268 1.6× 190 1.3× 62 0.5× 45 1.1k
Jerry E. Stewart United States 20 783 1.0× 317 0.8× 296 1.8× 168 1.1× 99 0.8× 66 1.2k
Robert Tressler United States 15 758 1.0× 280 0.7× 167 1.0× 141 0.9× 190 1.5× 20 1.3k
Taru Muranen United States 13 555 0.7× 383 0.9× 177 1.1× 97 0.6× 110 0.9× 25 1.1k
Lucia Borriello United States 16 474 0.6× 373 0.9× 274 1.6× 136 0.9× 255 2.0× 27 984
Bradford W. Ozanne United Kingdom 20 1.1k 1.4× 537 1.3× 199 1.2× 113 0.7× 166 1.3× 28 1.8k
Danny A. Zwijnenburg Netherlands 17 641 0.8× 234 0.6× 303 1.8× 337 2.2× 54 0.4× 23 965
Catherine Richon France 18 608 0.8× 391 1.0× 419 2.5× 131 0.9× 243 1.9× 32 1.2k
Markus Bredel United States 15 565 0.7× 251 0.6× 199 1.2× 192 1.3× 58 0.5× 28 914
Micaela Quarto Italy 16 1.5k 2.0× 773 1.9× 318 1.9× 51 0.3× 204 1.6× 18 1.9k

Countries citing papers authored by Karina J. Yoon

Since Specialization
Citations

This map shows the geographic impact of Karina J. Yoon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karina J. Yoon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karina J. Yoon more than expected).

Fields of papers citing papers by Karina J. Yoon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karina J. Yoon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karina J. Yoon. The network helps show where Karina J. Yoon may publish in the future.

Co-authorship network of co-authors of Karina J. Yoon

This figure shows the co-authorship network connecting the top 25 collaborators of Karina J. Yoon. A scholar is included among the top collaborators of Karina J. Yoon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karina J. Yoon. Karina J. Yoon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miller, Aubrey L., Dongquan Chen, Md. Iqbal Hossain, et al.. (2024). BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine. Cancer Letters. 592. 216919–216919. 7 indexed citations
2.
Nazam, Nazia, Raoud Marayati, Sarah Shirley, et al.. (2024). Novel PP2A-Activating Compounds in Neuroblastoma. Cancers. 16(22). 3836–3836.
3.
Stewart, Jerry E., Jamie M. Aye, Elizabeth Mroczek‐Musulman, et al.. (2023). Using 3D-bioprinted models to study pediatric neural crest-derived tumors. International Journal of Bioprinting. 9(4). 723–723. 4 indexed citations
4.
Marayati, Raoud, Jerry E. Stewart, Elizabeth Mroczek‐Musulman, et al.. (2022). Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma. Cancers. 14(8). 1952–1952. 11 indexed citations
5.
Stewart, Jerry E., et al.. (2022). Lerociclib diminishes stemness in pediatric sarcoma cell lines.. Journal of Clinical Oncology. 40(16_suppl). e22010–e22010.
6.
Miller, Aubrey L., Patrick L. Garcia, Dongquan Chen, et al.. (2021). The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers. 13(14). 3470–3470. 20 indexed citations
7.
Marayati, Raoud, et al.. (2021). PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma. Journal of Pediatric Surgery. 56(6). 1157–1164. 3 indexed citations
8.
Marayati, Raoud, Venkatram R. Atigadda, Jamie M. Aye, et al.. (2021). Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts. Journal of Pediatric Surgery. 56(6). 1165–1173. 5 indexed citations
9.
Marayati, Raoud, Jamie M. Aye, Jerry E. Stewart, et al.. (2021). EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth. PLoS ONE. 16(3). e0246244–e0246244. 21 indexed citations
10.
Marayati, Raoud, Jamie M. Aye, Jerry E. Stewart, et al.. (2021). PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma. Scientific Reports. 11(1). 5984–5984. 7 indexed citations
11.
Marayati, Raoud, Venkatram R. Atigadda, Jamie M. Aye, et al.. (2020). 9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts. Translational Oncology. 14(1). 100893–100893. 6 indexed citations
12.
Garcia, Patrick L., Aubrey L. Miller, & Karina J. Yoon. (2020). Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. Cancers. 12(5). 1327–1327. 47 indexed citations
13.
Miller, Aubrey L., Patrick L. Garcia, Robert C.A.M. van Waardenburg, et al.. (2019). The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. EBioMedicine. 44. 419–430. 84 indexed citations
14.
Marayati, Raoud, Jamie M. Aye, Jerry E. Stewart, et al.. (2019). Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts. Scientific Reports. 9(1). 13259–13259. 20 indexed citations
15.
Aye, Jamie M., Jerry E. Stewart, Joshua C. Anderson, et al.. (2019). The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor. Oncotarget. 10(53). 5534–5548. 6 indexed citations
16.
Waardenburg, Robert C.A.M. van, et al.. (2018). Sphingolipid metabolism and drug resistance in ovarian cancer. Cancer Drug Resistance. 1. 181–197. 23 indexed citations
17.
Landen, Charles N., Rebecca C. Arend, Ashwini A. Katre, et al.. (2018). FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer. Cancer Letters. 436. 75–86. 17 indexed citations
18.
Yoon, Karina J., et al.. (2015). The role of ICAM-2 in neuroblastoma. Oncoscience. 2(11). 915–916. 2 indexed citations
19.
Yoon, Karina J., Jianjun Qi, Joanna S. Remack, et al.. (2006). Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. Molecular Cancer Therapeutics. 5(6). 1577–1584. 4 indexed citations
20.
Aboody, Karen S., Elizabeth Garcia, Marianne Z. Metz, et al.. (2006). Development of a Tumor-Selective Approach to Treat Metastatic Cancer. PLoS ONE. 1(1). e23–e23. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Tanno Breakdown of academic impact, for papers by Jerry E. Stewart Breakdown of academic impact, for papers by Robert Tressler Breakdown of academic impact, for papers by Taru Muranen Breakdown of academic impact, for papers by Lucia Borriello Breakdown of academic impact, for papers by Bradford W. Ozanne Breakdown of academic impact, for papers by Danny A. Zwijnenburg Breakdown of academic impact, for papers by Catherine Richon Breakdown of academic impact, for papers by Markus Bredel Breakdown of academic impact, for papers by Micaela Quarto
Rankless by CCL
2026